Esken Pharmaceuticals Limited, a active public limited company, was established on 07 July 1992 in Gujarat, Gujarat, India. Engaging in drug formulation & development within the pharma sector, it holds CIN: U24231GJ1992PLC017941. Registered under ROC Roc Ahmedabad. it is unlisted. It has an authorized capital of ₹6.30 Cr and a paid-up capital of ₹1.59 Cr.
It upholds a compliant status. Employing 3 professional, Its leadership includes Pranavkumar Manilal Patel (Whole-Time Director), Ashishkumar Tribhovandas Patel (Whole-Time Director), Nigamkumar Babulal Patel (Whole-Time Director). Past directors included Manilal Kashiram Patel, Bharatkumar Manilal Patel. It holds no open charges and ₹2.84 Cr settled loans. Its latest AGM occurred on 30 September 2024, with the balance sheet filed on 31 March 2024. It is based at 322 G I D C Phase Iidediasan Mehsana, Gujarat, Gujarat, 384001.
U24231GJ1992PLC017941
017941
07 July 1992
₹6.30 Cr
₹1.59 Cr
Roc Ahmedabad
Unlisted
Active
Explore comprehensive insights into Esken Pharmaceuticals Limited — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.
Access Report
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Pranavkumar Manilal Patel | Whole-Time Director | 06 Jul 1997 | Current |
| Ashishkumar Tribhovandas Patel | Whole-Time Director | 06 Jul 1997 | Current |
| Nigamkumar Babulal Patel | Whole-Time Director | 06 Jul 1997 | Current |
| Name | Designation | Cessation | Status |
|---|---|---|---|
| Pramod Abcsdd | Director | 21 May 2010 | Past |
| Pramod Abcsdd | Managing Director | 12 May 2015 | Past |
Discover detailed profiles of directors and KMP - Unlock leadership insights today!
Esken Pharmaceuticals Limited, for the financial year ended 2020, experienced significant reduction in revenue, with a 51.95% decrease. The company also saw a substantial fall in profitability, with a 74.72% decrease in profit. The company's net worth observed a substantial decline by a decrease of 46.31%.
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
In 2019, Esken Pharmaceuticals had a promoter holding of 15.79% and a public holding of 84.21%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Reveal ownership structures and financial performance - Get instant access now!
₹0
₹28,400,000.00
| Date | Lender | Amount | Status |
|---|---|---|---|
| 23 May 2016 | Others | ₹2.25 Cr | Satisfied |
| 26 Feb 2009 | The Co-Operative Bank Of Mehsana Limited | ₹2.50 M | Satisfied |
| 05 Jul 2008 | The Co-Operative Bank Of Mehsana Limited | ₹2.50 M | Satisfied |
| 11 Jun 2007 | The Co-Op Bank Of Mehsana Ltd. | ₹0.90 M | Satisfied |
Explore comprehensive loan charge details -
Esken Pharmaceuticals has a workforce of 3 employees as of Mar 22, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Gain comprehensive insights into the Deals and Valuation data of Esken Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Esken Pharmaceuticals's trajectory.
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
The activity Esken Pharmaceuticals Limited last Annual general meeting of members was held on 30 Sep 2024 as per latest MCA records. was completed.
Progress on Esken Pharmaceuticals Limited has filed its annual Financial statements for the year ended 31 Mar 2024 with Roc Ahmedabad. was documented.
The activity A charge registered on 23 May 2016 via Charge ID 100028731 with Others was fully satisfied on 03 Sep 2020. was completed.
A charge with Others amounted to Rs. 2.25 Cr with Charge ID 100028731 was registered on 23 May 2016. was recorded as a recent event.
The activity A charge registered on 26 Feb 2009 via Charge ID 10147777 with The Co-Operative Bank Of Mehsana Limited was fully satisfied on 18 May 2016. was completed.
Progress on A charge registered on 05 Jul 2008 via Charge ID 10112748 with The Co-Operative Bank Of Mehsana Limited was fully satisfied on 18 May 2016. was documented.
The CIN of Esken Pharmaceuticals Limited is U24231GJ1992PLC017941.
Esken Pharmaceuticals Limited is headquartered at 322 G I D C Phase Iidediasan Mehsana, Gujarat, Gujarat, 384001.
Esken Pharmaceuticals Limited was incorporated on 07 July 1992.
The current directors of Esken Pharmaceuticals Limited are
The primary industry of Esken Pharmaceuticals Limited is Pharma.
Esken Pharmaceuticals Limited is unlisted.
The authorized capital of Esken Pharmaceuticals Limited is ₹6.30 Cr, and the paid-up capital is ₹1.59 Cr.
The compliance status of Esken Pharmaceuticals Limited is Compliant.
Search company & director profiles for free and gain access to critical business data.
Company Details
+91-XXXXXXXXXX